Fibrinogen Concentrate: Is It Standard Currency or Bitcoin in Bleeding Management?

Anesthesia and Analgesia

Volumn 127, Issue 3, 2018, Pages 603-604

  Henderson, Reney A ^a   Mazzeffi, Michael A ^a   Tanaka, Kenichi A ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; APROTININ; DROTRECOGIN; FIBRIN; FIBRINOGEN; FIBRINOGEN CONCENTRATE; SEALANT; THROMBIN; VON WILLEBRAND FACTOR; HEMOSTATIC AGENT;

AFIBRINOGENEMIA; BLEEDING; BLOOD CLOTTING DISORDER; CARDIOPULMONARY BYPASS; COST EFFECTIVENESS ANALYSIS; EDITORIAL; HEMOSTASIS; HEPATITIS C; HUMAN; HUMAN TISSUE; HYPOFIBRINOGENEMIA; MORBIDITY; MORTALITY; THORACIC AORTIC SURGERY; THROMBOELASTOGRAPHY; THROMBOELASTOMETRY; THROMBOSIS; VIRUS INFECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC);

FIBRINOGEN; HEMORRHAGE; HEMOSTATICS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85063376886     PISSN: 00032999     EISSN: 15267598     Source Type: Journal    
DOI: 10.1213/ANE.0000000000003660     Document Type: Editorial

References (21)

1. McMullan V, Alston RP. Editorial III: aprotinin and cardiac surgery: a sorry tale of evidence misused. Br J Anaesth. 2013;110:675-678.
2. Poole D, Bertolini G, Garattini S. Withdrawal of "Xigris" from the market: old and new lessons. J Epidemiol Community Health. 2012;66:571-572.
3. Yasunaga H. Risk of authoritarianism: fibrinogen-transmitted hepatitis C in Japan. Lancet. 2007;370:2063-2067.
4. Costa-Filho R, Hochleitner G, Wendt M, Teruya A, Spahn DR. Over 50 years of fibrinogen concentrate. Clin Appl Thromb Hemost. 2016;22:109-114.
5. Key NS, Negrier C. Coagulation factor concentrates: past, present, and future. Lancet. 2007;370:439-448.
6. Rousou JA. Use of fibrin sealants in cardiovascular surgery: a systematic review. J Card Surg. 2013;28:238-247.
7. Li JY, Gong J, Zhu F, et al. Fibrinogen concentrate in cardiovascular surgery: a meta-analysis of randomized controlled trials. Anesth Analg. 2018;127:612-621.
8. Rao G, Lopez-Jimenez F, Boyd J, et al; American Heart Association Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Surgery and Anesthesia; Council on Clinical Cardiology; Council on Functional Genomics and Translational Biology; and Stroke Council. Methodological standards for meta-analyses and qualitative systematic reviews of cardiac prevention and treatment studies: a scientific statement from the American Heart Association. Circulation. 2017;136:e172-e194.
9. Jeppsson A, Waldén K, Roman-Emanuel C, Thimour-Bergström L, Karlsson M. Preoperative supplementation with fibrinogen concentrate in cardiac surgery: a randomized controlled study. Br J Anaesth. 2016;116:208-214.
10. Sadeghi M, Atefyekta R, Azimaraghi O, et al. [A randomized, double blind trial of prophylactic fibrinogen to reduce bleeding in cardiac surgery]. Braz J Anesthesiol. 2014;64:253-257.
11. Karlsson M, Ternström L, Hyllner M, et al. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery: a prospective randomised pilot study. Thromb Haemost. 2009;102:137-144.
12. Bilecen S, de Groot JA, Kalkman CJ, et al. Effect of fibrinogen concentrate on intraoperative blood loss among patients with intraoperative bleeding during high-risk cardiac surgery: a randomized clinical trial. JAMA. 2017;317:738-747.
13. Rahe-Meyer N, Levy JH, Mazer CD, et al. Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double-blind phase III study of haemostatic therapy. Br J Anaesth. 2016;117:41-51.
14. Ranucci M, Baryshnikova E, Crapelli GB, Rahe-Meyer N, Menicanti L, Frigiola A; Surgical Clinical Outcome REsearch (SCORE) Group. Randomized, double-blinded, placebo-controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. J Am Heart Assoc. 2015;4:e002066.
15. Tanaka KA, Egan K, Szlam F, et al. Transfusion and hematologic variables after fibrinogen or platelet transfusion in valve replacement surgery: preliminary data of purified lyophilized human fibrinogen concentrate versus conventional transfusion. Transfusion. 2014;54:109-118.
16. Rahe-Meyer N, Solomon C, Hanke A, et al. Effects of fibrinogen concentrate as first-line therapy during major aortic replacement surgery: a randomized, placebo-controlled trial. Anesthesiology. 2013;118:40-50.
17. Rahe-Meyer N, Solomon C, Hanke A, et al. Effects of fibrinogen concentrate as first-line therapy during major aortic replacement surgery: a randomized, placebo-controlled trial: erratum. Anesthesiology. 2013;118:1244.
18. Sniecinski R, Szlam F, Chen EP, Bader SO, Levy JH, Tanaka KA. Antithrombin deficiency increases thrombin activity after prolonged cardiopulmonary bypass. Anesth Analg. 2008;106:713-718.
19. Pagano D, Milojevic M, Meesters MI, et al. 2017 EACTS/ EACTA Guidelines on patient blood management for adult cardiac surgery. Eur J Cardiothorac Surg. 2018;53:79-111.
20. Innerhofer P, Fries D, Mittermayr M, et al. Reversal of traumainduced coagulopathy using first-line coagulation factor concentrates or fresh frozen plasma (RETIC): a single-centre, parallel-group, open-label, randomised trial. Lancet Haematol. 2017;4:e258-e271.
21. Myles PS, Grocott MP, Boney O, Moonesinghe SR; COMPACStEP Group. Standardizing end points in perioperative trials: towards a core and extended outcome set. Br J Anaesth. 2016;116:586-589